Exl01 in Crohn's disease

What is Exl01?
EXL01 is a novel drug candidate containing an unmodified single strain of Faecalibacterium prausnitzii, a commensal bacterium being developed by Exeliom Biosciences as an oral therapy for Crohn’s disease, to prolong the maintenance of remission (steroid-induced maintenance treatment).

The EXL01-strain is manufactured using a GMP compliant proprietary culture medium, under strict anaerobic conditions.
The EXL01-drug substance is formulated in gastro-resistant capsules for oral administration, designed to enable targeted delivery into the intestines.

Learn more about F. praustnizii in Inflammatory Bowel Diseases
Learn more abouT Exl01


Exl01 in Immuno-Oncology



Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.